Skip to contentR
Relay Therapeutics, Inc.
R
RLAYRelay Therapeutics, Inc. Q3 2022 · 10-Q
Revenue$344.00K$344.00K−48.3% vs Q3 2021 Net Income-$84.17M-$84.17MN/M vs Q3 2021 EPS Diluted-$0.76-$0.76N/M vs Q3 2021 Operating Income-$85,892,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Relay Therapeutics, Inc. · CIK 1812364 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$68,240,000N/M Margins · derivedOperating margin-24968.6%−15810.9 pt vs Q3 2021
Net margin-24468.6%−15334.5 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 3, 2022 · 34 d after period end